Some retrospective studies [21–23] and a meta-analysis of retrospective trials [24] have suggested a benefit from adjuvant trastuzumab for patients with HER2-positive pT1a-b pN0 breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.